Crown Bioscience and The Jackson Laboratory Collaboration Enables Global Access to FATZO Mouse Model
Continued Collaboration Facilitates Global Distribution of Obesity, Metabolic Disease, and NASH Model and Priority Supply to CrownBio’s World-Class Cardiovascular, Obesity, and Metabolic Disease Platform
SAN DIEGO, March 05, 2019 (GLOBE NEWSWIRE) -- Crown Bioscience, a global drug discovery and development services company, providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research today announced an exclusive agreement with The Jackson Laboratory (JAX) to utilize its world-class distribution channels to make the FATZO mouse model available to researchers globally.
As CrownBio’s exclusive distributor of the FATZO model, JAX, the independent, nonprofit biomedical research organization will utilize its expertise in the breeding, production, and delivery of high-quality mouse models to increase worldwide access with immediate effect. As part of the agreement, JAX will provide a prioritized model supply to support CrownBio’s global service platform in obesity, diabetes and associated indications.
A unique and proprietary model to CrownBio, the FATZO model, is a translationally-relevant, inbred polygenic mouse model ideal for the study of obesity, metabolic syndrome and diabetes, and drug development. The model is sensitive to developing obesity and metabolic syndrome under the influence of a high-fat diet, which has been demonstrated to be a significant factor in the human development of these conditions. The model also exhibits human-like disease progression, making it an ideal candidate for modeling human metabolic syndrome.
“I am excited that our ongoing relationship with The Jackson Laboratory has resulted in this agreement and will enable easier access to FATZO, thereby accelerating discovery in obesity, diabetes, and NAFLD/NASH,” said Dr. Jim Wang, senior vice president of CrownBio’s Cardiovascular and Metabolic Disease division.
To learn more about the FATZO mouse and Crown’s Cardiovascular and Metabolic Disease platform, visit: www.crownbio.com/cvmd
About Crown Bioscience Inc.
Crown Bioscience is a global drug discovery and development service company providing translational platforms to advance oncology and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates.
Crown Bioscience Inc.
The Jackson Laboratory
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg saker fra GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra GlobeNewswire
Radient Technologies Inc. Announces Addition of Three Key Members to its Management Team25.3.2019 12:30:00 CET | Pressemelding
EDMONTON, Alberta, March 25, 2019 (GLOBE NEWSWIRE) -- Radient Technologies Inc. (“Radient” or the “Company”) (TSX Venture: RTI; OTCQX: RDDTF) is pleased to announce that it has appointed Mr. Adrian Marshall and Mr. James Blakelock to the joint role of Executive Vice President, Corporate Strategy and Planning, and Mr. Bill Wasson to the role of Senior Vice President, Capital Markets and Investor Relations. Working closely with Radient’s existing Management Team and Board of Directors, they will be instrumental in developing, driving and communicating the Company’s corporate strategy and global expansion. Denis Taschuk, CEO & President of Radient, commented: “These additions to our management team are very strategic in nature, and we consider ourselves fortunate to have attracted such top talent as we move forward with our global expansion plans. Both Mr. Marshall and Mr. Blakelock bring to Radient decades of experience working directly with some of the world’s leading rapid growth consu
Forterra Announces Rich Hunter as President of Drainage Pipe & Products and Vik Bhatia of Water Pipe & Products Segments25.3.2019 11:00:00 CET | Pressemelding
IRVING, Texas, March 25, 2019 (GLOBE NEWSWIRE) -- Forterra, Inc. (“Forterra” or the "Company”) (NASDAQ: FRTA), a leading manufacturer of water and drainage pipe and products in the United States and Eastern Canada, today announced the appointment of Rich Hunter as President of its Drainage Pipe & Products (“Drainage”) segment, and Vik Bhatia as President of its Water Pipe & Products (“Water”) segment. In their new roles, Rich and Vik will continue to report to Jeff Bradley, Chief Executive Officer. Hired as Chief Operating Officer in June 2018, Rich has successfully directed the operations team in delivering measurable improvements in cost, productivity and quality. Vik, who joined Forterra in August of 2017, has had several senior leadership roles, most recently providing focused commercial leadership in the development and execution of sales and customer service strategy for Water. Forterra CEO Jeff Bradley commented, “Rich and Vik have proven themselves as strong leaders who are bot
cPacket Networks Acquires Solarflare’s SolarCapture Appliance Business25.3.2019 10:00:00 CET | Pressemelding
Joint Solution Provides cPacket Customers with 40Gbps Visibility into High Speed Critical Networks and Retrospective Analysis of Operational and Security Issues SAN JOSE, Calif., March 25, 2019 (GLOBE NEWSWIRE) -- cPacket Networks, a leading provider of next-generation network performance monitoring and packet broker solutions, has entered into an agreement with Solarflare to acquire the company’s SolarCapture® Appliance business. Solarflare’s SolarCapture Appliance business provides network traffic capture capability for a variety of IT NetOps and SecOps applications including compliance, service-level-agreement monitoring, performance monitoring, security analytics, network forensics, and record keeping. Now an integral part of cPacket’s cStor (integrated packet-forensics for advanced real-time-analytics) product-line, the combined solution provides 100-percent lossless capture for speeds up to 40Gbps. “Making the SolarCapture Appliance technology a permanent addition to our cStor pr
Nasdaq, Inc. Announces Proposed Senior Notes Offering25.3.2019 10:00:00 CET | Pressemelding
NEW YORK, March 25, 2019 (GLOBE NEWSWIRE) -- Nasdaq, Inc. (the “Company”) (Nasdaq: NDAQ) today announced that it plans to offer, subject to market and other conditions, Euro-denominated senior notes (the “Offering”). The Company expects to use the net proceeds from the Offering to refinance indebtedness and for other general corporate purposes. J.P. Morgan Securities plc, Merrill Lynch International, Mizuho International plc and Skandinaviska Enskilda Banken AB (publ) will act as joint book-running managers for the Offering. HSBC Bank plc, ICBC Standard Bank Plc, Nordea Bank Abp, The Toronto-Dominion Bank and Wells Fargo Securities International Limited are acting as co-managers for the Offering. The Offering will be made pursuant to an effective shelf registration statement, previously filed by the Company with the U.S. Securities and Exchange Commission (the “SEC”). Before investing, you should read the prospectus supplement and accompanying prospectus, as well as other documents the
Epilog Laser Announces Exciting New Rebrand25.3.2019 08:00:00 CET | Pressemelding
Changes reflect evolving business and expansion of laser product offerings GOLDEN, Colo., March 25, 2019 (GLOBE NEWSWIRE) -- Epilog Laser, the leading producer of CO2 and fiber laser engraving, cutting and marking systems, announced today the launch of a new corporate brand identity including a redesign of the company’s website, logo, graphics, communications, and correspondence. “Since our inception in 1988, Epilog Laser has built a strong reputation for innovation and quality. We want our logo to tell the story of the manufacturing technology company that we have grown to be,” said Mike Dean, vice president of sales and marketing for Epilog Laser. “The new logo design reflects the modern technologies and advanced features that we are incorporating into our new product lines." “We believe at Epilog that the brand has evolved during the past thirty years. We want the brand and the logo to best reflect the technological achievements we’ve accomplished during those years and where we’re
CLS Presents MRI-Guided, Laser Ablation Solutions for Prostate Cancer at CME-Accredited Conferences in London, Paris & Amsterdam25.3.2019 08:00:00 CET | Pressemelding
More Than 1.3 Million New Cases of Prostate Cancer Worldwide in 2018 LUND, Sweden, March 25, 2019 (GLOBE NEWSWIRE) -- Clinical Laserthermia Systems AB (publ) (CLS) today announced it will be exhibiting and presenting its High Precision, Image-Guided Laser Ablation Solutions at three CME-Accredited Medical Conferences & Workshops in the UK, France, and Netherlands this April 2019. CLS Thermal Therapy products are currently in use at hospitals and clinics in the U.S. and EU for patient treatments and also undergoing several clinical trials. “CLS is excited to be participating in these three medical education events highlighting the latest MRI- and Ultra Sound-guided diagnostic techniques and treatments for prostate cancer,” said Lars-Erik Eriksson, CEO of CLS. ”Physicians are extremely interested in Image-guided therapies now that the latest technology advancements are enabling more precision, accuracy, and effectiveness for treating their patients.” CLS - April 2019 Conferences & Worksh